UB

Upstream Bio, Inc.

UPB·NASDAQ

$20.97

-5.9%
HealthcareBiotechnology

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

At a Glance

Live Snapshot
Market Cap$1.13B
EPS-0.7400
P/E Ratio-3.69
Earnings Date11/06/2025

upb

Capital Lease Obligations

Last Annual Value

1.83M

3-Year CAGR

169%

5-Year CAGR

81%

10-Year CAGR

35%

UB

Upstream Bio, Inc. Competitors Analysis of Capital Lease Obligations

UPB · NASDAQ
CompanyCapital Lease Obligations
CAGR 3Y
CAGR 5Y
CAGR 10Y
1.83M
244.1%N/AN/A 
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
28.69M
-18.7%4.6%N/A
SEPN logo
Septerna, Inc.
NASDAQ:SEPN
0.00
N/AN/AN/A
211.00K
-36.2%N/AN/A
0.00
N/AN/AN/A
65.26M
-17.9%-14.5%29.0%
0.00
N/AN/AN/A
UB

Upstream Bio, Inc. Fair Value Envelope

UPB · NASDAQ

Our analysis suggests that UPB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $20.97, this represents a potential HIDDEN relative to our calculated worth for Upstream Bio, Inc..

Intrinsic Value
Current Price: $20.97